Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 129 (3), 461-469

Does the Choice of Antiepileptic Drug Affect Survival in Glioblastoma Patients?

Affiliations

Does the Choice of Antiepileptic Drug Affect Survival in Glioblastoma Patients?

Kristin M Knudsen-Baas et al. J Neurooncol.

Abstract

Patients with glioblastoma (GBM) often suffer from symptomatic epilepsy. Older antiepileptic drugs (AEDs) which affect the enzyme system cytochrome P450 have been in extensive use, but there is an increasing focus on interactions with other drugs. This study investigated whether newer AEDs with little or no enzyme effect are increasingly preferred. Previous research has indicated that valproate improves survival in GBM. We investigated the impact of AEDs on overall survival in GBM patients. All GBM patients diagnosed in Norway 2004-2010 were included through a linkage of national registries, and follow-up data on the malignancy and drug usage were analyzed. In a multivariate cox proportional-hazards regression, AEDs were adjusted for each other and for relevant factors. Immortal time bias was eliminated with time-dependent variables. The study population was 1263 patients with histologically confirmed GBM. Carbamazepine was the most frequently prescribed AED to patients diagnosed with GBM during 2004-2006, while levetiracetam was increasingly prescribed to patients diagnosed later. Taking AEDs on a reimbursement code of epilepsy was not beneficial for survival. None of the six AEDs valproate, levetiracetam, carbamazepine, oxcarbazepine, lamotrigine or phenytoin significantly altered overall survival. There has been a shift in the prescriptions of AEDs to GBM patients from older to newer AEDs over time. We found no significant survival benefit in GBM patients neither from treatment with AEDs for epilepsy in general, nor from the usage of six separate AEDs.

Keywords: Antiepileptic drugs; Epilepsy; Glioblastoma; National registries; Overall survival.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Lancet Oncol. 2009 May;10 (5):459-66 - PubMed
    1. Lancet Neurol. 2007 May;6(5):421-30 - PubMed
    1. J Neurol. 2015 Jan;262(1):179-86 - PubMed
    1. Strahlenther Onkol. 2014 Oct;190(10):933-8 - PubMed
    1. Neurology. 2011 Sep 20;77(12 ):1156-64 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback